GLP-1 and Erectile Function: What the Research Shows

The question comes up constantly in men's health forums: "Will Ozempic affect my erections?" The answer from the research is more nuanced than a simple yes or no — and it's mostly good news. Here's what the clinical data, adverse event databases, and mechanistic studies actually tell us.

The Adverse Event Signal: Small but Real

A 2024 TriNetX database study found that prescribing semaglutide for weight loss in non-diabetic obese patients was associated with an increased risk of erectile dysfunction reporting. A FAERS (FDA Adverse Event Reporting System) analysis published in the International Journal of Impotence Research in 2025 looked at disproportionality signals across all GLP-1 agonists for male sexual dysfunction, including ED, orgasmic dysfunction, and decreased libido.

The semaglutide-specific ED incidence was approximately 1.4%. To put that in context: the background rate of ED in the general male population over age 40 is 40–52%. A 1.4% incidence signal in an adverse event database doesn't mean the drug causes ED — it means 1.4% of patients reported it while taking the drug, in a population where ED is already extremely common.

The Mechanism: GLP-1 Receptors in Reproductive Tissue

GLP-1 receptors exist in Leydig cells (which produce testosterone) and in cavernosal tissue. Theoretically, GLP-1 agonists could affect testosterone secretion or smooth muscle relaxation in the penis. However, the mechanistic research is still early-stage, and the clinical data doesn't show a consistent testosterone-lowering effect from GLP-1 therapy.

A 2026 review in Obesity Pillars raised a separate concern: the potential for GLP-1 medications to decrease sexual desire through their effects on reward pathways. The authors argued that because GLP-1s dampen hedonic eating through central nervous system reward modulation, they might similarly dampen sexual desire — which is also partially mediated by dopaminergic reward circuits. This is a plausible hypothesis but remains unconfirmed in controlled trials.

The Other Side: Weight Loss Often Improves Erections

Here's where the data gets encouraging. Obesity is one of the strongest independent risk factors for ED. Excess visceral fat increases aromatase activity (converting testosterone to estrogen), promotes systemic inflammation, damages endothelial function, and accelerates atherosclerosis — all of which impair erectile physiology.

Multiple studies demonstrate that sustained weight loss of 10% or more significantly improves erectile function scores. The pathways are well-characterized: improved nitric oxide bioavailability, reduced oxidative stress, better vascular compliance, and in many cases, measurable increases in total and free testosterone.

The clinical implication is straightforward: for the majority of obese men with ED, GLP-1-mediated weight loss is likely to improve erectile function over time, even if a small subset experiences transient effects in the early treatment period.

What to Do If You Notice Changes

If you start a GLP-1 medication and notice changes in erectile function or libido, the 2025 EAU guidelines recommend: get a comprehensive sexual history and physical exam, check early-morning fasting total testosterone, rule out other causes (medications, sleep apnea, stress, relationship factors), and consider PDE5 inhibitors as first-line treatment if ED is confirmed. If hypogonadism is identified, adjunctive TRT may be warranted.

Do not stop your GLP-1 medication without discussing it with your prescriber. The cardiovascular and metabolic benefits of continued therapy typically outweigh the small risk of sexual side effects.

The Verdict

The research shows a small adverse event signal for ED with GLP-1 medications — approximately 1.4% reporting rate with semaglutide. Mechanistic plausibility exists but isn't proven. Meanwhile, the weight-loss-driven improvement in erectile function is well-established and affects a much larger proportion of patients. For most men, the net effect of GLP-1 therapy on sexual function is positive. Monitor, communicate with your provider, and don't let a 1.4% signal override 15–22% body weight reduction and a 20% cardiovascular risk reduction.